📣 VC round data is live. Check it out!
- Public Comps
- Mentice
Mentice Valuation Multiples
Discover Mentice's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like SOFTMAX, OssDsign, Insung Information, Elutia and more.
Mentice Overview
About Mentice
Mentice AB is engaged in the provision of software and hardware simulation solutions for endovascular therapies. Its solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. It operates through three segments: Mentice VIST, Physical Sim, and Ankyras. Geographically majority of the revenue is generated from the Americas, then followed by EMEA.
Founded
1998
HQ

Employees
131
Website
Financials (LTM)
EV
$41M
Valuation Multiples
Start free trialMentice Financials
Mentice reported last 12-month revenue of $32M and EBITDA of $1M.
In the same LTM period, Mentice generated $29M in gross profit, $1M in EBITDA, and had net loss of ($2M).
Revenue (LTM)
Mentice P&L
In the most recent fiscal year, Mentice reported revenue of $31M and EBITDA of $472K.
Mentice is unprofitable as of last fiscal year, with gross margin of 87%, EBITDA margin of 2%, and net margin of (11%).
Financial data powered by Morningstar, Inc.
Mentice Stock Performance
Mentice has current market cap of $45M, and enterprise value of $41M.
Market Cap Evolution
Mentice's stock price is $1.62.
Mentice share price increased by 5.8% in the last 30 days, and decreased by 0.1% in the last year.
Mentice has an EPS (earnings per share) of $-0.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41M | $45M | 6.7% | 5.8% | 12.5% | -0.1% | $-0.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMentice Valuation Multiples
Mentice trades at 1.3x EV/Revenue multiple, and 31.3x EV/EBITDA.
EV / Revenue (LTM)
Mentice Financial Valuation Multiples
As of June 3, 2026, Mentice has market cap of $45M and EV of $41M.
Mentice has a P/E ratio of (19.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mentice Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Mentice Margins & Growth Rates
Mentice grew revenue by 8% and EBITDA by 436% in the last fiscal year.
In the most recent fiscal year, Mentice reported gross margin of 87%, EBITDA margin of 2%, and net margin of (11%).
Mentice Margins
Mentice Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Mentice Operational KPIs
Mentice's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Mentice's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mentice's Rule of X is 35% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Mentice Competitors
Mentice competitors include SOFTMAX, OssDsign, Insung Information, Elutia, Biohit, Data Horizon, Sensus Healthcare, Rocket Doctor AI, Baumer and InspireMD.
Most Mentice public comparables operate across Healthcare Software, Medical Devices, HealthTech, B2B SaaS, Vertical SaaS and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.0x | 1.0x | 8.5x | - | |||
| 1.3x | 1.4x | (6.5x) | (5.9x) | |||
| 0.2x | - | (38399.5x) | - | |||
| 1.8x | 1.8x | (1.7x) | (1.5x) | |||
| 2.3x | - | 10.9x | - | |||
| 3.0x | - | (4.9x) | - | |||
| 1.1x | 1.1x | (3.0x) | (2.9x) | |||
| 34.2x | 19.9x | (8.3x) | (9.9x) | |||
This data is available for Pro users. Sign up to see all Mentice competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Mentice
Mentice has acquired 4 companies to date.
Last acquisition by Mentice was on June 9th 2022. Mentice acquired Ankyras for $3M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Mentice
| Description | Ankyras is a medical technology company offering patient-specific simulation software for braided stents in intracranial aneurysm treatments. The platform simulates deployment dynamics, predicts occlusion rates, and optimizes implantation parameters using finite element analysis on patient CT angiography data. Developed for neurointerventionalists, it integrates with major imaging systems and supports Flow Re-Direction Endoluminal Device stents from MicroVention-Terumo. Based in Italy, Ankyras launched commercially in Europe in 2022 following CE Mark approval and partners with hospitals in Milan and Barcelona for validation studies. | - | Vascular Simulations is a Boston-based medical technology company that creates patient-specific 3D printed vascular models for realistic simulation of endovascular procedures using actual medical devices in physical anatomies replicating human vessels. | MSC - Medical Products is a designer and supplier of medical simulation devices targeting physician training and sales demonstrations. The company produces anatomical models, procedural trainers, and virtual reality simulators for cardiology, orthopedics, and surgical specialties. Distributed to hospitals and medical device firms, its products facilitate hands-on education to accelerate adoption of new therapies. |
| HQ Country | ||||
| HQ City | Barcelona | - | New York City, NY | Denver, CO |
| Deal Date | 9 Jun 2022 | 8 Oct 2020 | 1 Oct 2020 | 20 Dec 2017 |
| Valuation | $3M | $200K | $6M | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Mentice acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mentice
| When was Mentice founded? | Mentice was founded in 1998. |
| Where is Mentice headquartered? | Mentice is headquartered in Sweden. |
| How many employees does Mentice have? | As of today, Mentice has over 131 employees. |
| Is Mentice publicly listed? | Yes, Mentice is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Mentice? | Mentice trades under MNTC ticker. |
| When did Mentice go public? | Mentice went public in 2019. |
| Who are competitors of Mentice? | Mentice main competitors include SOFTMAX, OssDsign, Insung Information, Elutia, Biohit, Data Horizon, Sensus Healthcare, Rocket Doctor AI, Baumer, InspireMD. |
| What is the current market cap of Mentice? | Mentice's current market cap is $45M. |
| What is the current revenue of Mentice? | Mentice's last 12 months revenue is $32M. |
| What is the current revenue growth of Mentice? | Mentice revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Mentice? | Current revenue multiple of Mentice is 1.3x. |
| What is the current EBITDA of Mentice? | Mentice's last 12 months EBITDA is $1M. |
| What is Mentice's EBITDA margin? | Mentice's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Mentice? | Current EBITDA multiple of Mentice is 31.3x. |
| What is the current FCF of Mentice? | Mentice's last 12 months FCF is ($392K). |
| What is Mentice's FCF margin? | Mentice's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Mentice? | Current FCF multiple of Mentice is (104.9x). |
| How many companies Mentice has acquired to date? | As of June 2026, Mentice has acquired 4 companies. |
| What was the largest acquisition by Mentice? | $6M acquisition of Vascular Simulations on 1st October 2020 was the largest M&A Mentice has done to date. |
| In how many companies Mentice has invested to date? | Mentice hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Mentice
Lists including Mentice
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

